Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst
- Market cap
- $540.55K
Your view on STLNW
Overview
What the company does, where it operates, and who runs it.
About Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Daniel Virnich
- Headquarters
- 18000 Studebaker Road, Cerritos, CA, US
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Daniel Virnich
- Headquarters
- 18000 Studebaker Road, Cerritos, CA, US
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.
The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services.
It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies.
It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst. Starting points for Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst: EPS -$0.34, beta 2.95 — an Medical - Care Facilities name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst. Trailing twelve-month EPS for Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst stands at -$0.34. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterSep 2024 | Next quarterDec 2024 | This yearYear to Dec 2024 | Next yearYear to Dec 2025 |
|---|---|---|---|---|
| Average estimate | −$0.07 | −$0.08 | −$0.36 | −$0.59 |
| Lowest estimate | −$0.07 | −$0.08 | −$0.37 | −$0.60 |
| Highest estimate | −$0.07 | −$0.08 | −$0.35 | −$0.58 |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | — | — | — | — |
| Growth vs a year ago | — | — | — | — |
Revenue estimates
| Total | This quarterSep 2024 | Next quarterDec 2024 | This yearYear to Dec 2024 | Next yearYear to Dec 2025 |
|---|---|---|---|---|
| Average estimate | $107.54M | $109.15M | $414.70M | $500.58M |
| Lowest estimate | $105.66M | $107.52M | $410.14M | $495.07M |
| Highest estimate | $109.38M | $111.88M | $420.48M | $507.55M |
| Number of analysts | 2 | 2 | 2 | 1 |
| A year ago | — | — | — | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst. Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PAOGPAO Group, Inc. | Healthcare | OTC | $12,392 | ||
| PARKPark Dental Partners, Inc. Common Stock | Healthcare | NASDAQ | $94.3M | ||
| PHMBPharmaCom BioVet, Inc. | Healthcare | OTC | $1.1M | ||
| PIIIP3 Health Partners Inc. | Healthcare | NASDAQ | $5.5M | ||
| PIIIWP3 Health Partners Inc. | Healthcare | NASDAQ | $2.0M | ||
| PIQ.AXProteomics International Laboratories Ltd. | Healthcare | ASX | — | ||
| PMHSPolomar Health Services, Inc. | Healthcare | OTC | $4.5M | ||
| PNTGThe Pennant Group, Inc. | Healthcare | NASDAQ | $1.2B | ||
| PRMDPrimemd Inc. | Healthcare | OTC | $12,949 | ||
| RAFLFRaffles Medical Group Ltd | Healthcare | OTC | $1.4B | ||
| REG.AXRegis Healthcare Limited | Healthcare | ASX | — | ||
| RHC.AXRamsay Health Care Limited | Healthcare | ASX | — | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst.